Baker Bros. Advisors LP

Institutional investor · Portfolio as of Q2 2026

Q2 2026 biggest moves
  • RVMDRVMD

    Revolution Medicines

    Added 20%

    now 11% of portfolio

  • INSMINSM

    Insmed

    Added 19%

    now 4.7% of portfolio

  • ABVXABVX

    Abivax

    Sold out

    was 0.6% of portfolio

  • EWTXEWTX

    Edgewise Therapeutics

    Cut 44%

    now 0.8% of portfolio

39 changes in all

Top Holdings84 positions

Checking export access…
Activity:
INCY

Incyte Corporation

30.8M$3.5B17.5%$85.00+33.36%
30 qtrssince 2019-Q1
Increased
62
ONC
ONC
ADR

BeOne Medicines Ltd.

8.8M$2.5B12.6%$149.74+90.31%
30 qtrssince 2019-Q1
Increased
62
RVMD

Revolution Medicines, Inc.

11.4M$2.1B10.7%$56.67+230.50%
22 qtrssince 2021-Q1
Increased
73
MDGL

Madrigal Pharmaceuticals, Inc.

2.1M$1.2B5.8%$167.33+220.89%
30 qtrssince 2019-Q1
Increased
62
ACAD

ACADIA Pharmaceuticals Inc.

42.9M$1.1B5.4%$27.48-7.95%
30 qtrssince 2019-Q1
Increased
62
KYMR

Kymera Therapeutics, Inc.

8.7M$992.7M5.0%$40.89+180.41%
24 qtrssince 2020-Q3
Unchanged
0
INSM

Insmed Incorporated

8.8M$937.8M4.7%$89.20+19.52%
30 qtrssince 2019-Q1
Increased
69
CELC

Celcuity Inc.

7.9M$828.2M4.2%$24.80+321.80%
12 qtrssince 2023-Q3
Unchanged
0
KOD

Kodiak Sciences Inc

19.9M$776.1M3.9%$33.21+17.32%
30 qtrssince 2019-Q1
Unchanged
0
RYTM

Rhythm Pharmaceuticals, Inc.

5.6M$622.3M3.1%$24.17+359.45%
30 qtrssince 2019-Q1
Unchanged
0
PRAX

Praxis Precision Medicines, Inc.

1.8M$587M2.9%$208.46+60.60%
10 qtrssince 2024-Q1
Unchanged
0
ALKS

Alkermes plc

10M$524.6M2.6%$26.97+94.28%
9 qtrssince 2024-Q2
Unchanged
0
SMMT

Summit Therapeutics Inc.

32.8M$477.7M2.4%$12.42+17.30%
9 qtrssince 2024-Q2
Decreased
0
GRAL

GRAIL, Inc.

4M$275M1.4%$41.82+63.24%
7 qtrssince 2024-Q4
Unchanged
0
ABCL

AbCellera Biologics Inc.

33M$259.1M1.3%$16.46-52.31%
23 qtrssince 2020-Q4
Increased
53
IMVT

Immunovant, Inc.

5.4M$209.4M1.0%$21.09+82.72%
12 qtrssince 2023-Q3
Decreased
0
IDYA

IDEAYA Biosciences, Inc.

5M$186.7M0.9%$26.73+39.42%
16 qtrssince 2022-Q3
Increased
53
KNSA

Kiniksa Pharmaceuticals International, plc

2.8M$181.3M0.9%$18.84+239.49%
9 qtrssince 2024-Q2
Increased
43
ROIV

Roivant Sciences Ltd.

4.7M$166.9M0.8%$13.76+157.17%
15 qtrssince 2022-Q4
Decreased
0
ARWR

Arrowhead Pharmaceuticals, Inc.

2M$162.4M0.8%$33.82+140.98%
5 qtrssince 2025-Q2
Unchanged
0
$20B
AUM
84
Positions
Q2 2026
Filing
HI rating · 4.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$9,036,702,464-3.46942450012%
2025-Q2$10,307,840,45914.0663920281%
2025-Q3$13,838,782,04734.2549111237%
2025-Q4$17,078,624,10523.4113236772%
2026-Q1$17,415,689,9291.97361228825%
2026-Q2$19,955,238,55314.5819581903%
Activity profile
$ moved · Q2'26
New3%Increased78%Decreased11%Exited7%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.5 years
<1Q7%1-4Q11%1-2Y17%2Y+65%

Baker Bros. Advisors LP manages $20B across 84 positions as of Q2 2026. Top holdings: INCY (17.5%), ONC (12.6%), RVMD (10.7%). Fund DNA: Concentrated Value. HoldingsIntel Score: 4/5.0.

Top holdings by portfolio weight

Total AUM$20B
INCY17.48%
ONC12.57%
RVMD10.74%
MDGL5.77%
ACAD5.44%
KYMR4.97%
INSM4.70%
CELC4.15%
KOD3.89%
RYTM3.12%
Other2.94%

Portfolio allocation by GICS sector

Sectors1
Healthcare100.00%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Strong(4.0 / 5.0)
Holdings P&L43
Conviction57
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
INCYINCYIncyte Corporation
Q4 2024 → Q3 2026+23,632 shares+$1.7B
4Q
DSGNDSGNDesign Therapeutics, Inc.
Q4 2025 → Q3 2026+1.3M shares+$24.7M
3Q
ABCLABCLAbCellera Biologics Inc.
Q1 2026 → Q3 2026+5.5M shares+$387.5M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used